Companies: 10,795·Total market cap: $144.5T
Biogen Inc.

Biogen Inc.

BIIBNASDAQHealthcare● Active
$195.34
$-1.11(-0.57%)
Market Cap$28.8B
P/E Ratio—
52W High$205.97
52W Low$121.05
Cash on HandFinancialsRevenue

Biogen Inc. (BIIB) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

BIIB · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$3.82B▲ +60.7% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$3.01B
cashAndCashEquivalents
Short-Term Investments
$807.2M
shortTermInvestments
YoY Change vs Prior Year
+60.7%
vs prior fiscal year
Latest Quarter
$4.28B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$3.82BCash on Hand
Total Debt$6.95BTotal Debt
Net Cash / Net Debt−$3.13BNet Debt Position
Cash vs Debt Ratio
Cash 35%Debt 65%

Biogen Inc. carries a net debt position of $3.13B. Total debt ($6.95B) exceeds cash on hand ($3.82B). Biogen Inc. cash vs debt ratio: 35% cash / 65% debt.

Net Cash = Cash & ST Investments − Total Debt$3.82B − $6.95B = −$3.13B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
BIIB annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$3.82B+60.7%
Dec 31, 2024$2.38B+126.2%
Dec 31, 2023$1.05B-78.5%
Dec 31, 2022$4.89B+28.7%
Dec 31, 2021$3.80B+45.7%
BIIB cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Biogen Inc.
Biogen Inc.YOU
BIIB
$3.82B13.2%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Biogen Inc. (BIIB) cash on hand as of December 31, 2025 is $3.82B, comprising $3.01B in cash and cash equivalents (CCE) plus $807.2M in short-term investments — reported as Biogen Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Biogen Inc. cash reserves or cash position.

Biogen Inc. annual cash on hand history shows increased +60.7% in 2025: increased +60.7% in 2025. Biogen Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Biogen Inc. carries total debt of $6.95B against cash of $3.82B, resulting in a net debt position of -$3.13B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

BIIB cash on hand · 5 questions

As of December 31, 2025, Biogen Inc. (BIIB) has $3.82B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $3.01B in cash and cash equivalents (CCE) plus $807,200,000 in short-term investments. Latest quarter (March 31, 2026): $4.28B. Data sourced from the annual 10-K filing via FMP.

BIIB cash on handBIIB cash reservesBIIB cash 2025how much cash does BIIB have

▸ Source: FMP /balance-sheet-statement · US GAAP · Biogen Inc. · Biogen Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025